About Avedro
Avedro is a company based in Waltham (United States) founded in 2007 was acquired by Glaukos in August 2019. Avedro has raised $210.76 million across 11 funding rounds from investors including Glaukos, Flagship Pioneering and Orbimed. The company has 113 employees. Avedro operates in a competitive market with competitors including CorneaGen, EyeGate, Cellusion, EyeYon and CorNeat Vision, among others.
Funding Insights of Avedro
Avedro has successfully raised a total of $210.76M across 11 strategic funding rounds. The most recent funding activity was a Series E round of $25 million completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $210.76M
- Total Rounds 11
- Last Round Series E — $25M
- First Round $10M
(Apr 2009)
- Investors Count 13
Latest 10 of 11 funding rounds of Avedro with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | $25M | Series E | – | Lilly Asia Ventures | |
| Apr 2017 | $42M | Series E | – | Health Quest Capital | |
| Apr 2017 | – | Debt – Conventional | – | – | – |
| Nov 2015 | $32M | Series E | – | InterWest Partners, Orbimed | – |
| Mar 2015 | $13.69M | Series D | – | – | – |
| Mar 2013 | $43M | Series D | – | Abingworth | |
| Feb 2012 | $500,000 | Series C | – | – | – |
| Jul 2011 | $25M | Series C | – | SCP Vitalife | |
| May 2011 | $13.27M | Series B | – | – | – |
| Dec 2010 | $6.3M | Series A | – | – | – |
14 investors in total: 14 institutional.
Investors in Avedro
Avedro has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Glaukos, Flagship Pioneering and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Early-stage investing in IT and healthcare ventures. | – | interwest.com | - | |
Investments are focused on tech and life sciences startups. | – | healthquestcapital.com | Belmont, United States | |
VC firm investing in the US | – | prismventure.com | Westwood, United States | |
- | – | denovovc.com | - | |
A healthcare-focused investment firm supporting innovative company growth. | – | aperturevp.com | - | |
A venture capital firm focused on life science investments. | 2002 | scpvitalife.com | Tel-Aviv, Israel | |
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
- | – | echelon-ventures.com | - | |
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States |
Investor details for Avedro
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Avedro
4 dated milestones of Avedro across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Avedro is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series E, of $25.0M.
- Exit Acquired by Glaukos.
Competitors of Avedro
Avedro operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CorneaGen, EyeGate, Cellusion, EyeYon and CorNeat Vision, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| corneagen.com | 2017 | Seattle, United States | $42M | 205 | Therapeutic devices for corneal transplants are developed by CorneaGen. | |
| eyegatepharma.com | 1998 | Waltham, United States | $44.47M | 12 | Therapeutics and drug delivery systems for eye diseases are developed. | |
| cellusion.jp | 2015 | Minato, Japan | $29.71M | – | iPS cell-based technology for corneal endothelium regeneration is developed. | |
| eye-yon.com | 2011 | Ness Ziona, Israel | $35.1M | – | Ophthalmic devices for corneal edema treatment are developed. | |
| corneat.com | 2015 | – | $4M | – | Nanotechnology-based artificial corneal implants are developed for ophthalmic use. | |
| nueyne.com | 2017 | Seoul, South Korea | – | – | Medical devices using electrical stimulation for health conditions are developed. | |
| recornea.com | 2019 | Udine, Italy | $161,997 | – | Provider of corneal implants devices for the treatment of eye diseases | |
| surgilum.com | 2010 | Wilmington, United States | – | – | Creates innovative technologies for ophthalmic surgical devices. |
Detailed competitors of Avedro
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Avedro
Websites that share an audience with Avedro (avedro.com).
Websites whose visitors overlap most with Avedro. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| medisafeinternational.com | 93% | – | – | View details | |
| alimerasciences.com | 43% | – | – | View details |
Latest news on Avedro
Complete news archive for Avedro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Avedro
10 companies that operate in the same segment as Avedro (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Avedro
Avedro was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Avedro is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Avedro is a funded company, having raised a total of $210.76M across 11 funding rounds to date. The company's 1st funding round was a Series A of $6.3M, raised on Apr 2009.
Avedro has 113 employees.
Developer of corneal collagen cross-linking technology. Its products, the VibeX and KXL System for performing Lasik Xtra and accelerated cross-linking have been commercialized outside the US. It also received approval from the China FDA for its KXL system in Nov 2015.
Avedro has 14 investors. Key investors include Glaukos, Flagship Pioneering, Orbimed, Abingworth, and Lilly Asia Ventures.
Avedro operates through Avedro, Inc..
Yes. Avedro was acquired by Glaukos in August 2019.